Business
Further re Colchicine Litigation
Further re Colchicine Litigation.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n \nRNS Number : 7584Y Hikma Pharmaceuticals Plc 19 May 2016 \n\n \n \n \n \n \nHikma wins Mitigare / Colchicine patent infringement case\n \nLondon, 19 May 2016 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, today announces that the United States District Court for the District of Delaware has ruled in favour of Hikma and its wholly-owned subsidiary in the United States, West-Ward Pharmaceutical Corp., by granting their motion to dismiss claims made by Takeda Pharmaceuticals USA, Inc. for alleged infringement of patents covering methods of use of Takeda's colchicine product, Colcrys®. \n \nSince January 2015, Hikma has been marketing its own colchicine product under the brand name Mitigare™, as well as selling an authorised generic, increasing patient access to this important product in the United States.\nSaid Darwazah, Chairman and CEO of Hikma, said:\n\"I am very pleased with the ruling of the Delaware Court. This is a successful outcome and demonstrates our commitment to bringing more differentiated products to the US market.\"\n \n-- ENDS --\n \nEnquiries\nHikma Pharmaceuticals PLC \nSusan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760/ +44 7776 477050\nZeena Murad, Investor Relations Manager +44 (0) 20 7399 2768/ +44 7771 665277\n \nFTI Consulting &nb...